Article Information
History
- January 5, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Trie Arni Djunadi1,#,
- Youjin Oh1,#,
- Jeeyeon Lee1,2,
- Jisang Yu1,
- Liam Il-Young Chung1,
- Yeunho Lee3,
- Leeseul Kim4,
- Timothy Hong5,
- Soowon Lee6,
- Zunairah Shah1,
- Joo Hee Park1,
- Sung Mi Yoon1 and
- Young Kwang Chae1,*
- 1Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
- 2School of Medicine, Kyungpook National University, Daegu, Republic of Korea
- 3University of Hawai’i, Honolulu, Hawai’i, USA
- 4Ascension Saint Francis Hospital, Evanston, IL, USA
- 5Northwestern University, Evanston, IL, USA
- 6Baylor University, St, Waco, TX, USA
- ↵*Corresponding author
: Young Kwang Chae, MD, MPH, MBA, Department of Internal Medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, 645 N. Michigan Ave, Suite 1006, IL, USA, 60611, YCHAE{at}nm.org.
↵# The authors contributed equally.
Posted January 05, 2024.
Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
